Select your Language: हिन्दी
India

Serum Institute of India has developed an antidote to novel Coronavirus.

Shubham Jaiswal (shubhjaiswal729@gmail.com)

The Serum Institute of India said on Tuesday it plans this year to produce up to 60 million doses of a potential vaccine against the new coronavirus that is under clinical trial in Britain.
Serum is the world largest vaccines’ maker by volume, is mass-producing the vaccine candidate developed by the University of Oxford, which started testing it on humans last week, and is a leader within the global race to develop an antidote to the novel coronavirus.

Some 3.05 million people infected globally and 211,376 have died from COVID-19, the respiratory illness caused by the coronavirus, consistent with a Reuters tally.
While the Oxford vaccine, called, “ChAdOx1 nCoV-19”, is yet to be proven to figure against COVID-19, Serum decided to start out manufacturing it because it had shown success in animal trials and had progressed to the tests on human body, Serum Chief Executive Adar Poonawalla said.

Related Articles

Back to top button